Nothing Special   »   [go: up one dir, main page]

Hooft van Huijsduijnen et al., 2004 - Google Patents

Prospects for inhibitors of protein tyrosine phosphatase 1B as antidiabetic drugs

Hooft van Huijsduijnen et al., 2004

Document ID
2819359150029554595
Author
Hooft van Huijsduijnen R
Sauer W
Bombrun A
Swinnen D
Publication year
Publication venue
Journal of medicinal chemistry

External Links

Snippet

Protein tyrosine phosphatase 1B (PTP1B) emerged only 4 years ago as a new drug target for the treatment of diabetes and, possibly, obesity. The enzyme belongs to the family of tyrosine phosphatases, which consists of∼ 90 members. 1-3 Interestingly, this target had a …
Continue reading at pubs.acs.org (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)

Similar Documents

Publication Publication Date Title
Hooft van Huijsduijnen et al. Prospects for inhibitors of protein tyrosine phosphatase 1B as antidiabetic drugs
Jin et al. Azo-PROTAC: novel light-controlled small-molecule tool for protein knockdown
Singh et al. DcpS as a therapeutic target for spinal muscular atrophy
Philip et al. Cyclin-dependent kinase 8: A new hope in targeted cancer therapy? Miniperspective
Conti et al. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling
Seno et al. Pyrrolidine inhibitors of human cytosolic phospholipase A2
Scott et al. Discovery of a 3-(4-pyrimidinyl) indazole (MLi-2), an orally available and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor that reduces brain kinase activity
Hoover et al. Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase
Tonks PTP1B: from the sidelines to the front lines!
Desideri et al. Homoisoflavonoids: natural scaffolds with potent and selective monoamine oxidase-B inhibition properties
Davies et al. Monoacidic inhibitors of the Kelch-like ECH-associated protein 1: nuclear factor erythroid 2-related factor 2 (KEAP1: NRF2) protein–protein interaction with high cell potency identified by fragment-based discovery
Tang et al. Discovery and development of small-molecule inhibitors of glycogen synthase
von Geldern et al. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ETB selectivity
Ndubaku et al. Design of selective PAK1 inhibitor G-5555: improving properties by employing an unorthodox low-p K a polar moiety
Lovera et al. The different flexibility of c-Src and c-Abl kinases regulates the accessibility of a druggable inactive conformation
Granchi et al. A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017)
Gómez-Galeno et al. A potent and selective AMPK activator that inhibits de novo lipogenesis
Ebdrup et al. Synthesis and Structure− Activity relationship for a novel class of potent and selective carbamoyl-triazole based inhibitors of hormone sensitive lipase
Donella-Deana et al. Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity
Chaikuad et al. An unusual binding model of the methyl 9-anilinothiazolo [5, 4-f] quinazoline-2-carbimidates (EHT 1610 and EHT 5372) confers high selectivity for dual-specificity tyrosine phosphorylation-regulated kinases
Amato et al. N-pyridyl and pyrimidine benzamides as KCNQ2/Q3 potassium channel openers for the treatment of epilepsy
Maccari et al. Low molecular weight phosphotyrosine protein phosphatases as emerging targets for the design of novel therapeutic agents
Huber et al. Novel 3-arylideneindolin-2-ones as inhibitors of NAD+-dependent histone deacetylases (sirtuins)
Robertson et al. The rhodadyns, a new class of small molecule inhibitors of dynamin GTPase activity
Charlier et al. Structural insights into human 5-lipoxygenase inhibition: combined ligand-based and target-based approach